baricitinib vs tofacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT01710358 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.
Next expected readout: March 2027 · NCT04870203 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)
Result source: NCT02265705
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01262118 · Phase 1 · completed
This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.
Next expected readout: January 2027 · NCT06945666 (registry estimate)
Reported efficacy
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)
Result source: NCT01262118
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | tofacitinib |
|---|---|---|
| ACR20 | 61.7% vs 39.5%+22.2 vs placeboNCT0172105711 other results
| 52.7% vs 31.2%+21.5 vs placeboNCT00856544273 other results
|
| ACR50 | 44.1% vs 21.5%+22.6 vs placeboNCT0172105713 other results
| 32.7% vs 16%+16.7 vs placeboNCT00847613275 other results
|
| ACR70 | 24.2% vs 7.9%+16.3 vs placeboNCT0172105717 other results
| 25.4% vs 12.1%vs MTXNCT01039688271 other results
|
| DAS28-CRP remission | —Trial running · NCT04870203 | 23.0% vs 5.2%+17.8 vs placeboNCT00847613174 other results
|
| HAQ-DI, change | -0.5 vs -0.3−0.2 vs placeboNCT0172105711 other results
| -0.5 vs -0.2−0.3 vs placeboNCT00814307233 other results
|
| Modified Sharp score, change | 0.3 vs 0.8−0.5 vs placeboNCT017103582 other results
| 0.1 vs 0.5−0.3 vs placeboNCT008476137 other results
|
ACR20
- baricitinib
- 61.7% vs 39.5%+22.2 vs placeboNCT01721057
11 other results
- 55.4% vs 27.3% NCT01721044
- 65.9% vs 39.5% NCT01721057
- 69.6% vs 40.2% NCT01710358
- 58.6% vs 28.3% NCT02265705
- 76.7% vs 61.9% NCT01711359
- 78.1% vs 61.9% NCT01711359
- 46.3% vs 27.3% NCT01721044
- 44.8% vs 27.3% NCT01721044
- 48.9% vs 27.3% NCT01721044
- 73% vs 55.7% NCT01711359
- 72.6% vs 55.7% NCT01711359
- tofacitinib
- 52.7% vs 31.2%+21.5 vs placeboNCT00856544
273 other results
- 51.5% vs 28.3% NCT00853385
- 51.5% vs 25.3% NCT00847613
- 59.8% vs 26.7% NCT00814307
- 41.7% vs 24.4% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 52.5% vs 28.3% NCT00853385
- 61.8% vs 25.3% NCT00847613
- 65.7% vs 26.7% NCT00814307
- 48.1% vs 24.4% NCT00960440
- 52.7% vs 31.2% NCT00856544
- 50.8% vs 25.5% NCT00856544
- 56.3% vs 27.4% NCT00856544
- 60.7% vs 26.4% NCT00853385
- 56.3% vs 27.3% NCT00847613
- 56.9% vs 25.8% NCT00814307
- 54.0% vs 26.1% NCT00856544
- 46.5% vs 21.7% NCT00814307
- 38.6% vs 22.9% NCT00856544
- 41.2% vs 16.0% NCT00853385
- 41.4% vs 16.3% NCT00847613
- 42.4% vs 27.5% NCT00960440
- 29.6% vs 11.8% NCT00814307
- 27.3% vs 10.9% NCT00856544
- 27.7% vs 16.7% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 57.9% vs 25.5% NCT00856544
- 64.7% vs 27.4% NCT00856544
- 58.7% vs 26.4% NCT00853385
- 66.3% vs 27.3% NCT00847613
- 60.7% vs 25.8% NCT00814307
- 64.4% vs 26.1% NCT00856544
- 52.1% vs 21.7% NCT00814307
- 48.5% vs 22.9% NCT00856544
- 45.9% vs 16.0% NCT00853385
- 52.1% vs 16.3% NCT00847613
- 44.4% vs 27.5% NCT00960440
- 39.2% vs 11.8% NCT00814307
- 32.3% vs 10.9% NCT00856544
- 32.8% vs 16.7% NCT00960440
- 49.5% vs 49.3% NCT00853385
- 67.8% vs 51.1% NCT01039688
- 49.5% vs 47.2% NCT00853385
- 72.1% vs 55.4% NCT01039688
- 68.8% vs 47.3% NCT01039688
- 71.3% vs 50.5% NCT01039688
- 64.2% vs 46.7% NCT01039688
- 69.9% vs 51.6% NCT01039688
- 65.0% vs 45.1% NCT01039688
- 63.6% vs 42.4% NCT01039688
- 49.3% vs 21.2% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 49.5% vs 49.3% NCT00853385
- 71.6% vs 51.1% NCT01039688
- 50.5% vs 47.2% NCT00853385
- 73.6% vs 55.4% NCT01039688
- 66.2% vs 47.3% NCT01039688
- 76.1% vs 50.5% NCT01039688
- 66.0% vs 46.7% NCT01039688
- 77.9% vs 51.6% NCT01039688
- 62.2% vs 45.1% NCT01039688
- 71.6% vs 42.4% NCT01039688
- 58.3% vs 21.2% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 73.1% vs 15.4% NCT00687193
- 61.2% vs 23.7% NCT00550446
- 96.3% vs 14.3% NCT00603512
- 56.3% vs 36.2% NCT00413660
- 70.5% vs 29.2% NCT00147498
- 84.9% vs 15.4% NCT00687193
- 72.1% vs 23.7% NCT00550446
- 80.8% vs 14.3% NCT00603512
- 58.1% vs 36.2% NCT00413660
- 76.8% vs 29.2% NCT00147498
- 56.3% vs 36.2% NCT00413660
- 90.7% vs 15.4% NCT00687193
- 71.9% vs 23.7% NCT00550446
- 56% vs 36.2% NCT00413660
- 81.2% vs 29.2% NCT00147498
- 67.9% vs 15.4% NCT00687193
- 45.1% vs 23.7% NCT00550446
- 77.8% vs 14.3% NCT00603512
- 55.9% vs 36.2% NCT00413660
- 37.7% vs 15.4% NCT00687193
- 31.5% vs 23.7% NCT00550446
- 64.3% vs 14.3% NCT00603512
- 47.1% vs 36.2% NCT00413660
- 57.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 69.4% vs 32.4% NCT00550446
- 57.7% vs 47.1% NCT00413660
- 67.3% vs 35.3% NCT00550446
- 53.5% vs 43.1% NCT00413660
- 57.1% vs 23.7% NCT00550446
- 67.3% vs 11.5% NCT00687193
- 63.3% vs 27.1% NCT00550446
- 96.3% vs 21.4% NCT00603512
- 54.9% vs 33.3% NCT00413660
- 50% vs 28.9% NCT00147498
- 63.3% vs 25.4% NCT00550446
- 57.8% vs 37.7% NCT00413660
- 61.5% vs 9.6% NCT00687193
- 40.8% vs 27.1% NCT00550446
- 88.9% vs 10.7% NCT00603512
- 46.5% vs 24.6% NCT00413660
- 63.9% vs 30.8% NCT00147498
- 34.6% vs 5.8% NCT00687193
- 32.6% vs 15.3% NCT00550446
- 63.0% vs 10.7% NCT00603512
- 31.0% vs 15.9% NCT00413660
- 50.8% vs 20% NCT00147498
- 29.6% vs 3.6% NCT00603512
- 27.9% vs 12.3% NCT00147498
- 73.8% vs 47.1% NCT00550446
- 66.2% vs 47.1% NCT00413660
- 73.8% vs 32.4% NCT00550446
- 62.2% vs 47.1% NCT00413660
- 70.5% vs 35.3% NCT00550446
- 64.9% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 86.8% vs 11.5% NCT00687193
- 65.6% vs 27.1% NCT00550446
- 56.8% vs 33.3% NCT00413660
- 55.4% vs 37.7% NCT00413660
- 81.1% vs 9.6% NCT00687193
- 46.0% vs 24.6% NCT00413660
- 66% vs 5.8% NCT00687193
- 70.6% vs 28.9% NCT00147498
- 75.4% vs 30.8% NCT00147498
- 68.1% vs 20% NCT00147498
- 56.5% vs 12.3% NCT00147498
- 62.7% vs 47.1% NCT00413660
- 64.2% vs 47.1% NCT00413660
- 64.2% vs 43.1% NCT00413660
- 56.3% vs 33.3% NCT00413660
- 50% vs 37.7% NCT00413660
- 51.3% vs 24.6% NCT00413660
- 33.8% vs 15.9% NCT00413660
- 80.8% vs 21.4% NCT00603512
- 63.9% vs 25.4% NCT00550446
- 52.5% vs 27.1% NCT00550446
- 76.9% vs 10.7% NCT00603512
- 50.8% vs 15.3% NCT00550446
- 50% vs 10.7% NCT00603512
- 31.1% vs 15.9% NCT00413660
- 38.5% vs 3.6% NCT00603512
- 68.4% vs 47.1% NCT00550446
- 65.3% vs 47.1% NCT00413660
- 71.9% vs 32.4% NCT00550446
- 61.3% vs 47.1% NCT00413660
- 71.9% vs 35.3% NCT00550446
- 62.7% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 87% vs 11.5% NCT00687193
- 71.9% vs 27.1% NCT00550446
- 64% vs 33.3% NCT00413660
- 66.1% vs 28.9% NCT00147498
- 66.7% vs 25.4% NCT00550446
- 56% vs 37.7% NCT00413660
- 77.8% vs 9.6% NCT00687193
- 63.2% vs 27.1% NCT00550446
- 54.7% vs 24.6% NCT00413660
- 75.4% vs 30.8% NCT00147498
- 53.7% vs 5.8% NCT00687193
- 38.6% vs 15.3% NCT00550446
- 40% vs 15.9% NCT00413660
- 71.0% vs 20% NCT00147498
- 43.5% vs 12.3% NCT00147498
- 58.8% vs 47.1% NCT00550446
- 65.5% vs 47.1% NCT00413660
- 64.7% vs 32.4% NCT00550446
- 67.3% vs 47.1% NCT00413660
- 58.8% vs 35.3% NCT00550446
- 60% vs 43.1% NCT00413660
- 37.3% vs 23.7% NCT00550446
- 62.3% vs 11.5% NCT00687193
- 47.1% vs 27.1% NCT00550446
- 66.7% vs 21.4% NCT00603512
- 54.4% vs 33.3% NCT00413660
- 47.1% vs 25.4% NCT00550446
- 54.4% vs 37.7% NCT00413660
- 47.2% vs 9.6% NCT00687193
- 37.3% vs 27.1% NCT00550446
- 55.6% vs 10.7% NCT00603512
- 45.6% vs 24.6% NCT00413660
- 34% vs 5.8% NCT00687193
- 31.4% vs 15.3% NCT00550446
- 40.7% vs 10.7% NCT00603512
- 36.8% vs 15.9% NCT00413660
- 14.8% vs 3.6% NCT00603512
- 35.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 45.9% vs 32.4% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 51.4% vs 35.3% NCT00550446
- 63.3% vs 43.1% NCT00413660
- 35.2% vs 23.7% NCT00550446
- 37.7% vs 11.5% NCT00687193
- 37.0% vs 27.1% NCT00550446
- 67.9% vs 21.4% NCT00603512
- 50% vs 33.3% NCT00413660
- 38.9% vs 25.4% NCT00550446
- 44.3% vs 37.7% NCT00413660
- 35.8% vs 9.6% NCT00687193
- 22.2% vs 27.1% NCT00550446
- 50% vs 10.7% NCT00603512
- 37.1% vs 24.6% NCT00413660
- 18.9% vs 5.8% NCT00687193
- 16.7% vs 15.3% NCT00550446
- 82.6% vs 65.2% NCT01059864
- 76% vs 76.6% NCT01059864
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 32.1% vs 10.7% NCT00603512
- 21.4% vs 15.9% NCT00413660
- 28.6% vs 3.6% NCT00603512
- 60% vs 0% NCT00976599
- 71% vs 66.6% NCT02092467
- 70% vs 68% NCT02092467
- 69.9% vs 66.8% NCT02092467
- 68.7% vs 67.6% NCT02092467
- 67.4% vs 64.6% NCT02092467
- 67.3% vs 63.6% NCT02092467
- 65.6% vs 65.4% NCT02092467
- 57.2% vs 56% NCT02092467
- 65.7% vs 63.5% NCT02092467
- 66% vs 62.9% NCT02092467
- 64.1% vs 64.2% NCT02092467
- 64.3% vs 63.5% NCT02092467
- 62.3% vs 61.1% NCT02092467
- 61.6% vs 61.1% NCT02092467
- 62.2% vs 60.9% NCT02092467
- 53.6% vs 54.4% NCT02092467
- 44.9% vs 44% NCT02092467
- 36.8% vs 35.7% NCT02092467
- 29.8% vs 27.6% NCT02092467
- 23.2% vs 20.8% NCT02092467
- 16.7% vs 16% NCT02092467
- 11.2% vs 11.1% NCT02092467
- 5.8% vs 6.1% NCT02092467
- 1.8% vs 2.5% NCT02092467
- 0.3% vs 0.7% NCT02092467
- 68.1% vs 66.6% NCT02092467
- 69% vs 68% NCT02092467
- 68.9% vs 66.8% NCT02092467
- 69.5% vs 67.6% NCT02092467
- 66.9% vs 64.6% NCT02092467
- 68.1% vs 63.6% NCT02092467
- 65.5% vs 65.4% NCT02092467
- 59.5% vs 56% NCT02092467
- 63.3% vs 63.5% NCT02092467
- 63% vs 62.9% NCT02092467
- 61.7% vs 64.2% NCT02092467
- 61% vs 63.5% NCT02092467
- 60.5% vs 61.1% NCT02092467
- 57.9% vs 61.1% NCT02092467
- 58.2% vs 60.9% NCT02092467
- 49.3% vs 54.4% NCT02092467
- 40.3% vs 44% NCT02092467
- 33.3% vs 35.7% NCT02092467
- 27.2% vs 27.6% NCT02092467
- 22% vs 20.8% NCT02092467
- 16.3% vs 16% NCT02092467
- 11.4% vs 11.1% NCT02092467
- 6.9% vs 6.1% NCT02092467
- 2.5% vs 2.5% NCT02092467
- 1% vs 0.7% NCT02092467
ACR50
- baricitinib
- 44.1% vs 21.5%+22.6 vs placeboNCT01721057
13 other results
- 29.4% vs 13.1% NCT01721044
- 33.5% vs 12.7% NCT01721057
- 28.2% vs 8% NCT01721044
- 41.5% vs 21.5% NCT01721057
- 23% vs 13.1% NCT01721044
- 33.6% vs 12.7% NCT01721057
- 20.1% vs 8% NCT01721044
- 57.2% vs 37.6% NCT01711359
- 61.9% vs 37.6% NCT01711359
- 59.7% vs 43.3% NCT01711359
- 63.3% vs 43.3% NCT01711359
- 54.7% vs 32.9% NCT01711359
- 60% vs 32.9% NCT01711359
- tofacitinib
- 32.7% vs 16%+16.7 vs placeboNCT00847613
275 other results
- 32.7% vs 20% NCT00847613
- 33.8% vs 12.7% NCT00856544
- 36.7% vs 12.3% NCT00853385
- 32.4% vs 8.4% NCT00847613
- 28.0% vs 8.3% NCT00856544
- 31.1% vs 12.5% NCT00814307
- 27.3% vs 9.6% NCT00856544
- 34.2% vs 6.6% NCT00853385
- 28.8% vs 7.8% NCT00847613
- 26.5% vs 8.4% NCT00960440
- 26.1% vs 5.8% NCT00814307
- 23.1% vs 4.5% NCT00856544
- 17.4% vs 4.2% NCT00814307
- 11.6% vs 1.3% NCT00856544
- 14.9% vs 4.7% NCT00853385
- 16.8% vs 1.3% NCT00847613
- 12.9% vs 6.1% NCT00960440
- 5.8% vs 4.2% NCT00814307
- 5.8% vs 1.3% NCT00856544
- 7.7% vs 1.6% NCT00960440
- 41.1% vs 16% NCT00847613
- 44.0% vs 20% NCT00847613
- 36.6% vs 12.7% NCT00856544
- 34.7% vs 12.3% NCT00853385
- 43.7% vs 8.4% NCT00847613
- 33.3% vs 8.3% NCT00856544
- 36.8% vs 12.5% NCT00814307
- 34.0% vs 9.6% NCT00856544
- 27.6% vs 6.6% NCT00853385
- 36.3% vs 7.8% NCT00847613
- 27.8% vs 8.4% NCT00960440
- 33.9% vs 5.8% NCT00814307
- 29.8% vs 4.5% NCT00856544
- 24.0% vs 4.2% NCT00814307
- 18.1% vs 1.3% NCT00856544
- 16.3% vs 4.7% NCT00853385
- 18.4% vs 1.3% NCT00847613
- 17.3% vs 6.1% NCT00960440
- 12.9% vs 4.2% NCT00814307
- 8.1% vs 1.3% NCT00856544
- 5.5% vs 1.6% NCT00960440
- 36.7% vs 33.7% NCT00853385
- 49.9% vs 33.7% NCT01039688
- 35.7% vs 29.1% NCT00853385
- 49.9% vs 35.3% NCT01039688
- 50.7% vs 33.1% NCT01039688
- 46.6% vs 26.6% NCT01039688
- 48.0% vs 30.4% NCT01039688
- 40.1% vs 20.1% NCT01039688
- 49.0% vs 30.4% NCT01039688
- 32.6% vs 11.4% NCT01039688
- 18.0% vs 3.8% NCT01039688
- 49.3% vs 28.3% NCT01039688
- 35.7% vs 33.7% NCT00853385
- 55.6% vs 33.7% NCT01039688
- 37.2% vs 29.1% NCT00853385
- 56.9% vs 35.3% NCT01039688
- 54.3% vs 33.1% NCT01039688
- 56.4% vs 26.6% NCT01039688
- 51.8% vs 30.4% NCT01039688
- 50% vs 20.1% NCT01039688
- 50.5% vs 30.4% NCT01039688
- 40.1% vs 11.4% NCT01039688
- 28.0% vs 3.8% NCT01039688
- 49.2% vs 28.3% NCT01039688
- 36.7% vs 17.6% NCT00550446
- 39.4% vs 31.4% NCT00413660
- 32.7% vs 17.6% NCT00550446
- 38% vs 31.4% NCT00413660
- 34.7% vs 20.6% NCT00550446
- 38% vs 21.6% NCT00413660
- 46.2% vs 7.7% NCT00687193
- 38.8% vs 10.2% NCT00550446
- 81.5% vs 14.3% NCT00603512
- 36.6% vs 17.4% NCT00413660
- 34.7% vs 6.8% NCT00550446
- 44.2% vs 1.9% NCT00687193
- 24.5% vs 8.5% NCT00550446
- 70.4% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 17.9% vs 13.3% NCT00147498
- 14.3% vs 6.8% NCT00550446
- 31.0% vs 8.7% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 28.8% vs 1.9% NCT00687193
- 10.2% vs 5.1% NCT00550446
- 29.6% vs 3.6% NCT00603512
- 11.3% vs 2.9% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 11.5% vs 0% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 25.9% vs 0% NCT00603512
- 5.6% vs 2.9% NCT00413660
- 9.8% vs 3.1% NCT00147498
- 0% vs 0% NCT00603512
- 6.6% vs 3.1% NCT00147498
- 45.9% vs 17.6% NCT00550446
- 39.2% vs 31.4% NCT00413660
- 42.6% vs 17.6% NCT00550446
- 40.5% vs 31.4% NCT00413660
- 42.6% vs 20.6% NCT00550446
- 36.5% vs 21.6% NCT00413660
- 69.8% vs 7.7% NCT00687193
- 45.9% vs 10.2% NCT00550446
- 50.8% vs 6.8% NCT00550446
- 62.3% vs 1.9% NCT00687193
- 29.5% vs 8.5% NCT00550446
- 36.1% vs 6.8% NCT00550446
- 54.7% vs 1.9% NCT00687193
- 31.1% vs 5.1% NCT00550446
- 32.1% vs 0% NCT00687193
- 18.0% vs 1.7% NCT00550446
- 25% vs 2.9% NCT00413660
- 15% vs 2.9% NCT00413660
- 57.7% vs 14.3% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 50% vs 7.1% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 27.0% vs 8.7% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 20.3% vs 2.9% NCT00413660
- 26.9% vs 0% NCT00603512
- 4.0% vs 2.9% NCT00413660
- 45.1% vs 13.3% NCT00147498
- 50.7% vs 6.2% NCT00147498
- 42.0% vs 6.2% NCT00147498
- 29.0% vs 3.1% NCT00147498
- 18.8% vs 3.1% NCT00147498
- 46.3% vs 31.4% NCT00413660
- 47.8% vs 31.4% NCT00413660
- 41.8% vs 21.6% NCT00413660
- 36.3% vs 17.4% NCT00413660
- 32.5% vs 17.4% NCT00413660
- 27.5% vs 8.7% NCT00413660
- 7.7% vs 0% NCT00603512
- 54.4% vs 17.6% NCT00550446
- 46.7% vs 31.4% NCT00413660
- 59.6% vs 17.6% NCT00550446
- 48% vs 31.4% NCT00413660
- 56.1% vs 20.6% NCT00550446
- 40% vs 21.6% NCT00413660
- 72.2% vs 7.7% NCT00687193
- 50.9% vs 10.2% NCT00550446
- 44% vs 17.4% NCT00413660
- 43.9% vs 6.8% NCT00550446
- 66.7% vs 1.9% NCT00687193
- 49.1% vs 8.5% NCT00550446
- 41.3% vs 17.4% NCT00413660
- 30.4% vs 13.3% NCT00147498
- 42.1% vs 6.8% NCT00550446
- 32% vs 8.7% NCT00413660
- 53.6% vs 6.2% NCT00147498
- 46.3% vs 1.9% NCT00687193
- 40.4% vs 5.1% NCT00550446
- 26.7% vs 2.9% NCT00413660
- 42.0% vs 6.2% NCT00147498
- 22.2% vs 0% NCT00687193
- 17.5% vs 1.7% NCT00550446
- 17.3% vs 2.9% NCT00413660
- 23.2% vs 3.1% NCT00147498
- 8.7% vs 3.1% NCT00147498
- 44.1% vs 17.6% NCT00550446
- 34.5% vs 31.4% NCT00413660
- 44.1% vs 17.6% NCT00550446
- 45.5% vs 31.4% NCT00413660
- 38.2% vs 20.6% NCT00550446
- 43.6% vs 21.6% NCT00413660
- 26.4% vs 7.7% NCT00687193
- 25.5% vs 10.2% NCT00550446
- 44.4% vs 14.3% NCT00603512
- 29.4% vs 17.4% NCT00413660
- 17.6% vs 6.8% NCT00550446
- 37.7% vs 1.9% NCT00687193
- 21.6% vs 8.5% NCT00550446
- 29.6% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 15.7% vs 6.8% NCT00550446
- 29.4% vs 8.7% NCT00413660
- 22.6% vs 1.9% NCT00687193
- 13.7% vs 5.1% NCT00550446
- 22.2% vs 3.6% NCT00603512
- 16.2% vs 2.9% NCT00413660
- 9.4% vs 0% NCT00687193
- 7.8% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 5.9% vs 2.9% NCT00413660
- 3.7% vs 0% NCT00603512
- 10.8% vs 17.6% NCT00550446
- 44.9% vs 31.4% NCT00413660
- 18.9% vs 17.6% NCT00550446
- 38.8% vs 31.4% NCT00413660
- 18.9% vs 20.6% NCT00550446
- 38.8% vs 21.6% NCT00413660
- 13.5% vs 7.7% NCT00687193
- 11.1% vs 10.2% NCT00550446
- 32.1% vs 14.3% NCT00603512
- 22.9% vs 17.4% NCT00413660
- 13.0% vs 6.8% NCT00550446
- 11.5% vs 1.9% NCT00687193
- 13.0% vs 8.5% NCT00550446
- 28.6% vs 7.1% NCT00603512
- 17.1% vs 17.4% NCT00413660
- 14.8% vs 6.8% NCT00550446
- 10% vs 8.7% NCT00413660
- 9.6% vs 1.9% NCT00687193
- 9.3% vs 5.1% NCT00550446
- 10.7% vs 3.6% NCT00603512
- 4.3% vs 2.9% NCT00413660
- 1.9% vs 0% NCT00687193
- 1.9% vs 1.7% NCT00550446
- 7.1% vs 0% NCT00603512
- 1.4% vs 2.9% NCT00413660
- 67.4% vs 45.7% NCT01059864
- 48% vs 42.6% NCT01059864
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 7.1% vs 0% NCT00603512
- 40% vs 0% NCT00976599
- 43.4% vs 39.8% NCT02092467
- 42.6% vs 39.8% NCT02092467
- 44.8% vs 40.1% NCT02092467
- 41.6% vs 36.7% NCT02092467
- 43.5% vs 42% NCT02092467
- 36.3% vs 31.7% NCT02092467
- 41.7% vs 41.9% NCT02092467
- 27.6% vs 23.2% NCT02092467
- 42.7% vs 40.8% NCT02092467
- 42.6% vs 41.1% NCT02092467
- 41.2% vs 42% NCT02092467
- 40.2% vs 40.9% NCT02092467
- 41.4% vs 40.8% NCT02092467
- 40.9% vs 38.7% NCT02092467
- 40.7% vs 40.5% NCT02092467
- 35.8% vs 35.8% NCT02092467
- 29% vs 29.2% NCT02092467
- 24.1% vs 23.8% NCT02092467
- 19.5% vs 18.5% NCT02092467
- 13.7% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 6.9% vs 7.1% NCT02092467
- 3.6% vs 3.8% NCT02092467
- 1.1% vs 1.9% NCT02092467
- 0.2% vs 0.5% NCT02092467
- 44.9% vs 39.8% NCT02092467
- 44.7% vs 39.8% NCT02092467
- 45.9% vs 40.1% NCT02092467
- 42.2% vs 36.7% NCT02092467
- 44.2% vs 42% NCT02092467
- 38.5% vs 31.7% NCT02092467
- 42.8% vs 41.9% NCT02092467
- 31% vs 23.2% NCT02092467
- 42.3% vs 40.8% NCT02092467
- 41.3% vs 41.1% NCT02092467
- 41.8% vs 42% NCT02092467
- 42% vs 40.9% NCT02092467
- 38.9% vs 40.8% NCT02092467
- 40.4% vs 38.7% NCT02092467
- 39.7% vs 40.5% NCT02092467
- 33% vs 35.8% NCT02092467
- 26.4% vs 29.2% NCT02092467
- 22% vs 23.8% NCT02092467
- 18.6% vs 18.5% NCT02092467
- 14.4% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 7.1% vs 7.1% NCT02092467
- 4.7% vs 3.8% NCT02092467
- 1.4% vs 1.9% NCT02092467
- 0.4% vs 0.5% NCT02092467
ACR70
- baricitinib
- 24.2% vs 7.9%+16.3 vs placeboNCT01721057
17 other results
- 16.9% vs 3.4% NCT01721044
- 18.1% vs 3.1% NCT01721057
- 11.3% vs 2.3% NCT01721044
- 25.3% vs 7.9% NCT01721057
- 13.2% vs 3.4% NCT01721044
- 17.9% vs 3.1% NCT01721057
- 12.6% vs 2.3% NCT01721044
- 42.1% vs 25.2% NCT01711359
- 46% vs 25.2% NCT01711359
- 42.1% vs 21.4% NCT01711359
- 39.5% vs 21.4% NCT01711359
- 30.8% vs 15.7% NCT01711359
- 33.5% vs 15.7% NCT01711359
- 29% vs 0% NCT01469013
- 29% vs 0% NCT01469013
- 21% vs 0% NCT01469013
- 13% vs 0% NCT01469013
- tofacitinib
- 25.4% vs 12.1%vs MTXNCT01039688
271 other results
- 37.3% vs 12.1% NCT01039688
- 13.2% vs 3.2% NCT00856544
- 19.9% vs 1.9% NCT00853385
- 14.6% vs 1.3% NCT00847613
- 11.9% vs 3.2% NCT00856544
- 15.3% vs 5.8% NCT00814307
- 8.4% vs 1.9% NCT00856544
- 12.2% vs 1.9% NCT00853385
- 10.7% vs 2.6% NCT00847613
- 13.6% vs 1.5% NCT00960440
- 10.0% vs 3.3% NCT00814307
- 9% vs 1.3% NCT00856544
- 5.0% vs 1.7% NCT00814307
- 3.5% vs 0% NCT00856544
- 2.6% vs 0.9% NCT00853385
- 3.9% vs 0% NCT00847613
- 7.6% vs 0% NCT00960440
- 2.1% vs 0% NCT00814307
- 0.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 16.2% vs 3.2% NCT00856544
- 21.9% vs 1.9% NCT00853385
- 22.3% vs 1.3% NCT00847613
- 18.1% vs 3.2% NCT00856544
- 20.3% vs 5.8% NCT00814307
- 14.2% vs 1.9% NCT00856544
- 14.8% vs 1.9% NCT00853385
- 17.1% vs 2.6% NCT00847613
- 10.5% vs 1.5% NCT00960440
- 19.0% vs 3.3% NCT00814307
- 10.4% vs 1.3% NCT00856544
- 9.1% vs 1.7% NCT00814307
- 7.1% vs 0% NCT00856544
- 4.1% vs 0.9% NCT00853385
- 3.6% vs 0% NCT00847613
- 6.8% vs 0% NCT00960440
- 4.6% vs 0% NCT00814307
- 2.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 23.0% vs 16.6% NCT00853385
- 28.7% vs 15.4% NCT01039688
- 18.4% vs 11.1% NCT00853385
- 29.2% vs 13.2% NCT01039688
- 30.1% vs 17.0% NCT01039688
- 32.2% vs 15.9% NCT01039688
- 19.9% vs 5.5% NCT01039688
- 32.2% vs 17.6% NCT01039688
- 16.2% vs 3.3% NCT01039688
- 5.2% vs 0.6% NCT01039688
- 34.1% vs 15.4% NCT01039688
- 23.5% vs 16.6% NCT00853385
- 37.9% vs 15.4% NCT01039688
- 21.9% vs 11.1% NCT00853385
- 37.9% vs 13.2% NCT01039688
- 37.9% vs 17.0% NCT01039688
- 36.6% vs 15.9% NCT01039688
- 26.6% vs 5.5% NCT01039688
- 36.8% vs 17.6% NCT01039688
- 23.0% vs 3.3% NCT01039688
- 9.2% vs 0.6% NCT01039688
- 37.6% vs 15.4% NCT01039688
- 22.4% vs 11.8% NCT00550446
- 21.1% vs 9.8% NCT00413660
- 18.4% vs 8.8% NCT00550446
- 23.9% vs 13.7% NCT00413660
- 20.4% vs 0% NCT00550446
- 18.3% vs 9.8% NCT00413660
- 26.9% vs 1.9% NCT00687193
- 14.3% vs 3.4% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 18.3% vs 5.8% NCT00413660
- 16.3% vs 1.7% NCT00550446
- 25% vs 1.9% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 11.3% vs 5.8% NCT00413660
- 8.9% vs 8.9% NCT00147498
- 4.1% vs 1.7% NCT00550446
- 16.9% vs 4.3% NCT00413660
- 13.1% vs 3.1% NCT00147498
- 17.3% vs 0% NCT00687193
- 2.0% vs 1.7% NCT00550446
- 14.8% vs 0% NCT00603512
- 0% vs 1.4% NCT00413660
- 9.8% vs 1.5% NCT00147498
- 1.9% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 11.1% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 4.9% vs 1.5% NCT00147498
- 0% vs 0% NCT00603512
- 1.6% vs 0% NCT00147498
- 37.7% vs 11.8% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 31.1% vs 8.8% NCT00550446
- 24.3% vs 13.7% NCT00413660
- 29.5% vs 0% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 49.1% vs 1.9% NCT00687193
- 24.6% vs 3.4% NCT00550446
- 12.2% vs 5.8% NCT00413660
- 37.7% vs 1.9% NCT00687193
- 16.2% vs 5.8% NCT00413660
- 9.5% vs 4.3% NCT00413660
- 26.4% vs 0% NCT00687193
- 11.5% vs 1.7% NCT00550446
- 9.4% vs 0% NCT00687193
- 3.3% vs 0% NCT00550446
- 27.4% vs 8.9% NCT00147498
- 27.5% vs 3.1% NCT00147498
- 21.7% vs 1.5% NCT00147498
- 10.1% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 28.4% vs 9.8% NCT00413660
- 28.4% vs 13.7% NCT00413660
- 22.4% vs 9.8% NCT00413660
- 23.8% vs 5.8% NCT00413660
- 17.5% vs 5.8% NCT00413660
- 12.5% vs 4.3% NCT00413660
- 12.5% vs 1.4% NCT00413660
- 2.5% vs 0% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 26.2% vs 1.7% NCT00550446
- 18.0% vs 1.7% NCT00550446
- 26.9% vs 3.6% NCT00603512
- 19.7% vs 1.7% NCT00550446
- 7.7% vs 0% NCT00603512
- 14.9% vs 1.4% NCT00413660
- 3.9% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 3.9% vs 0% NCT00603512
- 33.3% vs 11.8% NCT00550446
- 32% vs 9.8% NCT00413660
- 31.6% vs 8.8% NCT00550446
- 28% vs 13.7% NCT00413660
- 33.3% vs 0% NCT00550446
- 24% vs 9.8% NCT00413660
- 51.9% vs 1.9% NCT00687193
- 26.3% vs 3.4% NCT00550446
- 24% vs 5.8% NCT00413660
- 21.1% vs 1.7% NCT00550446
- 40.7% vs 1.9% NCT00687193
- 24.6% vs 1.7% NCT00550446
- 16% vs 5.8% NCT00413660
- 14.3% vs 8.9% NCT00147498
- 17.5% vs 1.7% NCT00550446
- 16% vs 4.3% NCT00413660
- 21.7% vs 3.1% NCT00147498
- 16.7% vs 0% NCT00687193
- 8.8% vs 1.7% NCT00550446
- 13.3% vs 1.4% NCT00413660
- 17.4% vs 1.5% NCT00147498
- 7.4% vs 0% NCT00687193
- 7.0% vs 0% NCT00550446
- 6.7% vs 0% NCT00413660
- 4.3% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 23.5% vs 11.8% NCT00550446
- 23.6% vs 9.8% NCT00413660
- 17.6% vs 8.8% NCT00550446
- 29.1% vs 13.7% NCT00413660
- 26.5% vs 0% NCT00550446
- 21.8% vs 9.8% NCT00413660
- 13.2% vs 1.9% NCT00687193
- 11.8% vs 3.4% NCT00550446
- 14.8% vs 3.6% NCT00603512
- 20.6% vs 5.8% NCT00413660
- 7.8% vs 1.7% NCT00550446
- 13.2% vs 1.9% NCT00687193
- 3.9% vs 1.7% NCT00550446
- 7.4% vs 3.6% NCT00603512
- 14.7% vs 5.8% NCT00413660
- 2.0% vs 1.7% NCT00550446
- 13.2% vs 4.3% NCT00413660
- 3.8% vs 0% NCT00687193
- 5.9% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 7.3% vs 1.4% NCT00413660
- 0% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 3.7% vs 0% NCT00603512
- 1.5% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 8.1% vs 11.8% NCT00550446
- 28.6% vs 9.8% NCT00413660
- 10.8% vs 8.8% NCT00550446
- 20.4% vs 13.7% NCT00413660
- 10.8% vs 0% NCT00550446
- 16.3% vs 9.8% NCT00413660
- 7.5% vs 1.9% NCT00687193
- 5.6% vs 3.4% NCT00550446
- 7.1% vs 3.6% NCT00603512
- 4.3% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 5.7% vs 1.9% NCT00687193
- 9.3% vs 1.7% NCT00550446
- 3.6% vs 3.6% NCT00603512
- 8.6% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 1.4% vs 4.3% NCT00413660
- 1.9% vs 0% NCT00687193
- 0% vs 1.7% NCT00550446
- 0% vs 0% NCT00687193
- 1.9% vs 0% NCT00550446
- 34.8% vs 30.4% NCT01059864
- 20% vs 19.1% NCT01059864
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 3.6% vs 0% NCT00603512
- 2.9% vs 1.4% NCT00413660
- 0% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 6.7% vs 0% NCT00976599
- 23.2% vs 19.6% NCT02092467
- 22.5% vs 20.1% NCT02092467
- 24.7% vs 21% NCT02092467
- 19.4% vs 16.1% NCT02092467
- 24.6% vs 22.4% NCT02092467
- 17.4% vs 13.7% NCT02092467
- 24.9% vs 22.2% NCT02092467
- 10.4% vs 7.8% NCT02092467
- 24% vs 22.6% NCT02092467
- 25.7% vs 23.6% NCT02092467
- 25.4% vs 24.7% NCT02092467
- 24.5% vs 24.5% NCT02092467
- 24.9% vs 24.2% NCT02092467
- 25.5% vs 23.3% NCT02092467
- 25.8% vs 23.6% NCT02092467
- 21.5% vs 20.5% NCT02092467
- 17.6% vs 16.4% NCT02092467
- 14.8% vs 13.7% NCT02092467
- 10.9% vs 11% NCT02092467
- 8.8% vs 8.1% NCT02092467
- 5.4% vs 6.3% NCT02092467
- 4% vs 4.4% NCT02092467
- 1.7% vs 2.4% NCT02092467
- 0.5% vs 1% NCT02092467
- 0.1% vs 0.3% NCT02092467
- 25.6% vs 19.6% NCT02092467
- 25.2% vs 20.1% NCT02092467
- 26.8% vs 21% NCT02092467
- 22.7% vs 16.1% NCT02092467
- 26.2% vs 22.4% NCT02092467
- 18.4% vs 13.7% NCT02092467
- 25.4% vs 22.2% NCT02092467
- 13.3% vs 7.8% NCT02092467
- 26.5% vs 22.6% NCT02092467
- 26.8% vs 23.6% NCT02092467
- 27.3% vs 24.7% NCT02092467
- 26.9% vs 24.5% NCT02092467
- 23.6% vs 24.2% NCT02092467
- 24.8% vs 23.3% NCT02092467
- 23.5% vs 23.6% NCT02092467
- 20.5% vs 20.5% NCT02092467
- 15.7% vs 16.4% NCT02092467
- 13.4% vs 13.7% NCT02092467
- 11.2% vs 11% NCT02092467
- 8.7% vs 8.1% NCT02092467
- 5.7% vs 6.3% NCT02092467
- 3.9% vs 4.4% NCT02092467
- 2.6% vs 2.4% NCT02092467
- 1% vs 1% NCT02092467
- 0.3% vs 0.3% NCT02092467
DAS28-CRP remission
- baricitinib
- —Trial running · NCT04870203
- tofacitinib
- 23.0% vs 5.2%+17.8 vs placeboNCT00847613
174 other results
- 20.4% vs 5.2% NCT00847613
- 11.3% vs 2.0% NCT00847613
- 36.4% vs 5.2% NCT00847613
- 26.9% vs 5.2% NCT00847613
- 9.1% vs 2.0% NCT00847613
- 38.4% vs 18.5% NCT01039688
- 37.1% vs 17.4% NCT01039688
- 38.4% vs 19.0% NCT01039688
- 37.6% vs 19.6% NCT01039688
- 36.5% vs 20.6% NCT01039688
- 36.2% vs 17.4% NCT01039688
- 31.3% vs 15.2% NCT01039688
- 25.9% vs 9.8% NCT01039688
- 20.4% vs 5.4% NCT01039688
- 7.4% vs 2.7% NCT01039688
- 43.9% vs 18.5% NCT01039688
- 44.7% vs 17.4% NCT01039688
- 44.7% vs 19.0% NCT01039688
- 49.2% vs 19.6% NCT01039688
- 49.5% vs 20.6% NCT01039688
- 45.7% vs 17.4% NCT01039688
- 47.2% vs 15.2% NCT01039688
- 37.8% vs 9.8% NCT01039688
- 28.7% vs 5.4% NCT01039688
- 14.1% vs 2.7% NCT01039688
- 65.9% vs 30% NCT00550446
- 22% vs 15% NCT00550446
- 41.5% vs 19.4% NCT00413660
- 68.9% vs 16.7% NCT00550446
- 20% vs 5.6% NCT00550446
- 35.1% vs 13.9% NCT00413660
- 69.6% vs 35% NCT00550446
- 28.3% vs 15% NCT00550446
- 24.1% vs 8.1% NCT00413660
- 62.2% vs 6.7% NCT00550446
- 24.4% vs 6.7% NCT00550446
- 16.7% vs 6.7% NCT00413660
- 65.8% vs 3.3% NCT00550446
- 21.7% vs 4.3% NCT00550446
- 66.7% vs 9.7% NCT00550446
- 14.9% vs 4.4% NCT00550446
- 19.4% vs 6.9% NCT00413660
- 56.4% vs 5.9% NCT00550446
- 8.9% vs 1.9% NCT00550446
- 13.6% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 4.4% vs 1.9% NCT00550446
- 8.1% vs 3.3% NCT00413660
- 62.5% vs 2.7% NCT00550446
- 4.2% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 72.7% vs 30% NCT00550446
- 36.4% vs 15% NCT00550446
- 36.5% vs 19.4% NCT00413660
- 88.7% vs 16.7% NCT00550446
- 43.4% vs 5.6% NCT00550446
- 37.1% vs 13.9% NCT00413660
- 78.2% vs 35% NCT00550446
- 36.4% vs 15% NCT00550446
- 30.2% vs 8.1% NCT00413660
- 75.6% vs 6.7% NCT00550446
- 33.3% vs 6.7% NCT00550446
- 32.3% vs 6.7% NCT00413660
- 90.7% vs 3.3% NCT00550446
- 31.6% vs 4.3% NCT00550446
- 78.6% vs 9.7% NCT00550446
- 21.4% vs 4.4% NCT00550446
- 21.3% vs 6.9% NCT00413660
- 79.5% vs 5.9% NCT00550446
- 24.1% vs 1.9% NCT00550446
- 24.2% vs 3.5% NCT00413660
- 83.7% vs 5.7% NCT00550446
- 17.5% vs 1.9% NCT00550446
- 19.1% vs 3.3% NCT00413660
- 71.1% vs 2.7% NCT00550446
- 5% vs 0% NCT00550446
- 4.4% vs 3.3% NCT00413660
- 32.7% vs 19.4% NCT00413660
- 30.9% vs 13.9% NCT00413660
- 29.1% vs 8.1% NCT00413660
- 24.6% vs 6.7% NCT00413660
- 20.9% vs 6.9% NCT00413660
- 10.1% vs 3.5% NCT00413660
- 10% vs 3.3% NCT00413660
- 4.0% vs 3.3% NCT00413660
- 84.6% vs 30% NCT00550446
- 50% vs 15% NCT00550446
- 39.3% vs 19.4% NCT00413660
- 76.9% vs 16.7% NCT00550446
- 42.3% vs 5.6% NCT00550446
- 38.6% vs 13.9% NCT00413660
- 82.4% vs 35% NCT00550446
- 43.1% vs 15% NCT00550446
- 37.9% vs 8.1% NCT00413660
- 68.6% vs 6.7% NCT00550446
- 40.4% vs 6.7% NCT00550446
- 37.1% vs 6.7% NCT00413660
- 79.4% vs 3.3% NCT00550446
- 38.5% vs 4.3% NCT00550446
- 75% vs 9.7% NCT00550446
- 41.5% vs 4.4% NCT00550446
- 23.9% vs 6.9% NCT00413660
- 67.6% vs 5.9% NCT00550446
- 32.7% vs 1.9% NCT00550446
- 22.7% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 15.1% vs 1.9% NCT00550446
- 16.9% vs 3.3% NCT00413660
- 66.7% vs 2.7% NCT00550446
- 7.0% vs 0% NCT00550446
- 13.2% vs 3.3% NCT00413660
- 46.4% vs 30% NCT00550446
- 39.3% vs 15% NCT00550446
- 35.7% vs 19.4% NCT00413660
- 58.6% vs 16.7% NCT00550446
- 20.7% vs 5.6% NCT00550446
- 43.2% vs 13.9% NCT00413660
- 53.3% vs 35% NCT00550446
- 30% vs 15% NCT00550446
- 41.9% vs 8.1% NCT00413660
- 42.9% vs 6.7% NCT00550446
- 8.9% vs 6.7% NCT00550446
- 30.9% vs 6.7% NCT00413660
- 53.3% vs 3.3% NCT00550446
- 8.5% vs 4.3% NCT00550446
- 46.7% vs 9.7% NCT00550446
- 12.8% vs 4.4% NCT00550446
- 22.0% vs 6.9% NCT00413660
- 43.3% vs 5.9% NCT00550446
- 12.8% vs 1.9% NCT00550446
- 19.7% vs 3.5% NCT00413660
- 33.3% vs 5.7% NCT00550446
- 6.5% vs 1.9% NCT00550446
- 14.8% vs 3.3% NCT00413660
- 33.3% vs 2.7% NCT00550446
- 4% vs 0% NCT00550446
- 3.2% vs 3.3% NCT00413660
- 33.3% vs 30% NCT00550446
- 16.7% vs 15% NCT00550446
- 23.1% vs 19.4% NCT00413660
- 46.2% vs 16.7% NCT00550446
- 19.2% vs 5.6% NCT00550446
- 20.5% vs 13.9% NCT00413660
- 48.1% vs 35% NCT00550446
- 22.2% vs 15% NCT00550446
- 14.3% vs 8.1% NCT00413660
- 22.2% vs 6.7% NCT00550446
- 9.3% vs 6.7% NCT00550446
- 6.6% vs 6.7% NCT00413660
- 26.3% vs 3.3% NCT00550446
- 10.9% vs 4.3% NCT00550446
- 25.6% vs 9.7% NCT00550446
- 2.1% vs 4.4% NCT00550446
- 7.9% vs 6.9% NCT00413660
- 20.5% vs 5.9% NCT00550446
- 8.5% vs 1.9% NCT00550446
- 3.2% vs 3.5% NCT00413660
- 30% vs 5.7% NCT00550446
- 6% vs 1.9% NCT00550446
- 4.6% vs 3.3% NCT00413660
- 25.6% vs 2.7% NCT00550446
- 1.9% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 16.7% vs 19.4% NCT00413660
- 0% vs 13.9% NCT00413660
- 11.1% vs 8.1% NCT00413660
- 15.4% vs 19.4% NCT00413660
- 15.4% vs 13.9% NCT00413660
- 23.1% vs 8.1% NCT00413660
- 25% vs 19.4% NCT00413660
- 28.6% vs 13.9% NCT00413660
- 9.5% vs 8.1% NCT00413660
- 24% vs 22.4% NCT04413617
- 40.8% vs 22.4% NCT04413617
HAQ-DI, change
- baricitinib
- -0.5 vs -0.3−0.2 vs placeboNCT01721057
11 other results
- -0.4 vs -0.2 NCT01721044
- -0.5 vs -0.3 NCT01721057
- -0.4 vs -0.2 NCT01721044
- -0.7 vs -0.3 NCT01710358
- -0.6 vs -0.3 NCT02265705
- -1.0 vs -0.7 NCT01711359
- -0.9 vs -0.7 NCT01711359
- -0.5 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.3 vs -0.1 NCT01469013
- tofacitinib
- -0.5 vs -0.2−0.3 vs placeboNCT00814307
233 other results
- -0.5 vs -0.2 NCT00856544
- -0.5 vs -0.2 NCT00853385
- -0.3 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.5 vs -0.2 NCT00814307
- -0.5 vs -0.2 NCT00856544
- -0.6 vs -0.2 NCT00853385
- -0.4 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.8 vs -0.6 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -0.8 vs -0.7 NCT01039688
- -0.7 vs -0.3 NCT01039688
- -0.5 vs -0.2 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.6 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.8 vs -0.3 NCT01039688
- -0.6 vs -0.2 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.5 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.4 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.6 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.5 vs -0.2 NCT00550446
- -0.5 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00147498
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.4 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.3 vs 0.1 NCT00687193
- -0.2 vs -0.0 NCT00550446
- -0.3 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00147498
- -0.1 vs 0 NCT00603512
- -0.3 vs -0.1 NCT00147498
- -0.6 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.4 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.6 vs -0.2 NCT00550446
- -0.6 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.5 vs -0.2 NCT00550446
- -0.5 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00687193
- -0.4 vs -0.1 NCT00550446
- -0.4 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.2 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.4 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.1 NCT00147498
- -0.6 vs -0.1 NCT00147498
- -0.4 vs -0.1 NCT00147498
- -0.7 vs -0.4 NCT00413660
- -0.7 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00413660
- -0.6 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0 NCT00603512
- -0.8 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.8 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00413660
- -0.8 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.7 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.5 vs 0.0 NCT00687193
- -0.6 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.4 vs 0.1 NCT00687193
- -0.4 vs -0.0 NCT00550446
- -0.2 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00147498
- -0.3 vs -0.1 NCT00147498
- -0.5 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.3 NCT00413660
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.3 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.2 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.6 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00550446
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.0 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.1 vs 0.0 NCT00687193
- -0.1 vs -0.1 NCT00550446
- -0.2 vs -0.1 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.1 vs -0.0 NCT00550446
- -0.1 vs -0.0 NCT00603512
- -0.1 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT01484561
- 0.1 vs -0.1 NCT01484561
- -0.4 vs -0.0 NCT01484561
- -0.5 vs -0.4 NCT00413660
- -0.4 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.1 vs -0.4 NCT00413660
- -0.1 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.3 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.4 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
Modified Sharp score, change
- baricitinib
- 0.3 vs 0.8−0.5 vs placeboNCT01710358
2 other results
- 0.4 vs 0.6 NCT01711359
- 0.3 vs 0.6 NCT01711359
- tofacitinib
- 0.1 vs 0.5−0.3 vs placeboNCT00847613
7 other results
- 0.1 vs 0.5 NCT00847613
- 0.2 vs 0.7 NCT01039688
- 0.1 vs 0.7 NCT01039688
- 0.4 vs 1.2 NCT01039688
- 0.6 vs 2.1 NCT01039688
- 0.2 vs 1.2 NCT01039688
- 0.3 vs 2.1 NCT01039688
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. baricitinib: 11 of 11 rows · tofacitinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib Rows use multiple source trials | tofacitinib Rows use multiple source trials |
|---|---|---|
| Boolean Remission responder rate · % of participants | 15.6% (n=487) vs NA placebo @ 52wka,b,c NCT01710358 · Phase 3 2 other source trials17% (n=159) vs 11.4% (n=210) Methotrexate @ 52wk NCT01711359 · Phase 3 20.9% (n=215) vs 11.4% (n=210) Methotrexate @ 52wk NCT01711359 · Phase 3 · combination | 11.22% (n=1455) vs 9.12% (n=1451) TNFi @ 52wk5 mg BIDd,a,b,c NCT02092467 · Phase 4 show 1 more dose13.06% (n=1456) vs 9.12% (n=1451) TNFi @ 52wk10 mg BID NCT02092467 · Phase 4 |
| CDAI absolute change · score | -26.44 vs NA placebo score @ 52wka,b,c NCT01710358 · Phase 3 2 other source trials-28.94 vs -21.95 Methotrexate score @ 52wk NCT01711359 · Phase 3 -30.72 vs -21.95 Methotrexate score @ 52wk NCT01711359 · Phase 3 · combination | -28.52 vs -27.73 TNFi score @ 52wk5 mg BIDd,a,b,c NCT02092467 · Phase 4 show 1 more dose-29.38 vs -27.73 TNFi score @ 52wk10 mg BID NCT02092467 · Phase 4 |
| DAS28-CRP absolute change · score | -2.74 vs -2.01 Methotrexate score @ 24wkd,e,b NCT01711359 · Phase 3 show 1 more dose-2.82 vs -2.01 Methotrexate score @ 24wk NCT01711359 · Phase 3 · combination | -2.66 vs -2.53 PF-06651600 score @ 24wk11mg MRd,e,b NCT04413617 · Phase 2 · registry result, not featured evidence show 1 more dose-3.05 vs -2.53 PF-06651600 score @ 24wk400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination |
| DAS28-ESR absolute change · score | -2.84 vs -2.32 Methotrexate score @ 52wkd,b NCT01711359 · Phase 3 show 1 more dose-3.22 vs -2.32 Methotrexate score @ 52wk NCT01711359 · Phase 3 · combination | -2.78 vs -2.2 MTX score @ 52wk5 mg BIDd,b NCT01039688 · Phase 3 show 1 more dose-3.05 vs -2.2 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| FACIT-Fatigue absolute change · score | 10.8 vs NA placebo score @ 52wkb,c NCT01710358 · Phase 3 2 other source trials11.3 vs 9.1 Methotrexate score @ 52wk NCT01711359 · Phase 3 12.6 vs 9.1 Methotrexate score @ 52wk NCT01711359 · Phase 3 · combination | 8.75 vs 6.89 MTX score @ 52wk5 mg BIDd,b,c NCT01039688 · Phase 3 show 1 more dose9.18 vs 6.89 MTX score @ 52wk10 mg BID NCT01039688 · Phase 3 |
| SDAI absolute change · score | -23.78 vs -14.55 placebo score @ 24wk4 mgd,a,b,c,f NCT01721057 · Phase 3 show 1 more dose-21.87 vs -14.55 placebo score @ 24wk2 mg NCT01721057 · Phase 3 | -32.27 vs -32.27 TNFi score @ 273wk5 mg BIDd,a,b,c,f NCT02092467 · Phase 4 show 1 more dose-32.12 vs -32.27 TNFi score @ 273wk10 mg BID NCT02092467 · Phase 4 |
| SDAI Remission responder rate · % of participants | 22.6% (n=487) vs NA placebo @ 52wka,b,c NCT01710358 · Phase 3 | 15.89% (n=1455) vs 13.92% (n=1451) TNFi @ 52wk5 mg BIDd,a,b,c NCT02092467 · Phase 4 show 1 more dose18.69% (n=1456) vs 13.92% (n=1451) TNFi @ 52wk10 mg BID NCT02092467 · Phase 4 |
| Dropout rate | 5.9%Baricitinibg NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 15%Baricitinib NCT01711359 · Phase 3 19.5%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 6.2%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 10.1%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 8.3%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 9.8%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 51.7%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 51.1%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 55.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 60.8%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 33.7%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 94.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 75.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 70.2%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 95.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 100%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 76.9%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 72.8%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 0%g NCT01262118 · Phase 1 show 80 more results4.9%5 mg NCT00814307 · Phase 3 11%10 mg NCT00814307 · Phase 3 17.9%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 20.8%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 26.5%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 21.4%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 n/a: no completion milestone5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 n/a: no completion milestone10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 19.5%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 23.1%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 28%10 mg BID NCT01039688 · Phase 3 27.7%5 mg BID NCT02092467 · Phase 4 31.5%10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.2%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 56.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 50.8%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 3.8% NCT02281552 · Phase 3 · registry result, not featured evidence 36.6%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 37.1%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 6.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 7.8%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 9.1%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 6.3% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.7%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 8%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 4.9%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.3%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 9.6%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 18.5%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 17.9%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 25%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 17.9%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 9.9%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.7%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 12.5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 12%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 9.9%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 4.9%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 24.6%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 13%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 9.3% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.7%Baricitinibg NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 6.3%Baricitinib NCT01711359 · Phase 3 11.2%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 1.4%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 4.4%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 5.6%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 4%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 13.5%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 12.6%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 8.3%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 5.7%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 6%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 12.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 21.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 18.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 11.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 14.5%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 16.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | —g NCT01262118 · Phase 1 show 80 more results1.2%5 mg NCT00814307 · Phase 3 3.7%10 mg NCT00814307 · Phase 3 6.3%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 9.1%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 11.8%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 11.9%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 11.2%5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 8.2%10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 9%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 9%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 9.8%10 mg BID NCT01039688 · Phase 3 —5 mg BID NCT02092467 · Phase 4 —10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 23.1%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 2.9% NCT02281552 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 22.9%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 1%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 1%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination — NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.5%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.8%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 14.3%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 14.3%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 1.4%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5.3%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.4%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 10.1%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 8.7%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 1% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | —Baricitinibg NCT01710358 · Phase 3 show 43 more results0%Baricitinib Follow-up NCT01710358 · Phase 3 5.3%Baricitinib Treatment A NCT01710358 · Phase 3 3.8%BaricitinibTreatment B NCT01710358 · Phase 3 7.5%Baricitinib NCT01711359 · Phase 3 7.9%Baricitinib + MTX NCT01711359 · Phase 3 · combination 0%Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination 0%Baricitinib - Follow-up NCT01711359 · Phase 3 2.8%4 mg NCT02265705 · Phase 3 1.7%4 mg NCT02265705 · Phase 3 2.5%4 mg NCT02265705 · Phase 3 9.5%Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 0%4 mg NCT01469013 · Phase 2 4.2%2 mg NCT01469013 · Phase 2 4.2%8 mg NCT01469013 · Phase 2 0%1 mg NCT01469013 · Phase 2 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 4.5%4 mg NCT01721057 · Phase 3 2.6%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 0%2 mg NCT01721057 · Phase 3 —4 mg NCT01721044 · Phase 3 0%4 mg NCT01721044 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 11.1%2 mg NCT01721044 · Phase 3 4.6%2 mg NCT01721044 · Phase 3 31.3%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 29.5%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 23.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 22.9%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 20%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 30%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 37.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 27.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 0%g NCT01262118 · Phase 1 show 80 more results—5 mg NCT00814307 · Phase 3 —10 mg NCT00814307 · Phase 3 —5 mg NCT00856544 · Phase 3 1.6%5 mg NCT00856544 · Phase 3 2.2%5 mg NCT00856544 · Phase 3 2.9%5 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 2.2%10 mg NCT00856544 · Phase 3 2.8%10 mg NCT00856544 · Phase 3 2.5%10 mg NCT00856544 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 4.3%5 mg twice daily NCT00853385 · Phase 3 4.2%5 mg twice daily NCT00853385 · Phase 3 5.9%5 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 3.2%10 mg twice daily NCT00853385 · Phase 3 4%10 mg twice daily NCT00853385 · Phase 3 5%10 mg twice daily NCT00853385 · Phase 3 —5 mg NCT00847613 · Phase 3 5%5 mg NCT00847613 · Phase 3 3.5%5 mg NCT00847613 · Phase 3 3.7%5 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 2.3%10 mg NCT00847613 · Phase 3 3.3%10 mg NCT00847613 · Phase 3 3.2%10 mg NCT00847613 · Phase 3 —5 mg NCT00960440 · Phase 3 4%5 mg NCT00960440 · Phase 3 1.5%5 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 4%10 mg NCT00960440 · Phase 3 1.5%10 mg NCT00960440 · Phase 3 10.7%5 mg BID NCT01039688 · Phase 3 10.8%10 mg BID NCT01039688 · Phase 3 25.6%5 mg BID NCT02092467 · Phase 4 28.8%10 mg BID NCT02092467 · Phase 4 3.8%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 1.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 2.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.4%5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 30.8%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 29.7%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 4.8% NCT02281552 · Phase 3 · registry result, not featured evidence 29.1%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 26.7%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 2.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 0%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5.5%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence 0% NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 1.6%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 7%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 2.9%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.4%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.7%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.6%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 5.6%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 6%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 7.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 2%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.8%1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 4.3%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 7.2%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 2.1% NCT01484561 · Phase 1 · registry result, not featured evidence 0%CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence 0%Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | g alanine aminotransferase increased 0% (placebo 0%) anaemia 0% (placebo 0%) back pain 0% (placebo 0%) NCT01710358 · Phase 3 show 30 more resultsnasopharyngitis 7.6% (placebo 6.1%) urinary tract infection 4.3% (placebo 0%) bronchitis 3.9% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 5.7% (placebo 6.1%) upper respiratory tract infection 3.1% (placebo 0%) bronchitis 2.8% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 10.1% upper respiratory tract infection 7.5% gastroenteritis 6.3% NCT01711359 · Phase 3 nasopharyngitis 9.8% nausea 9.3% upper respiratory tract infection 7.4% NCT01711359 · Phase 3 · combination abdominal discomfort 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT01711359 · Phase 3 · combination 4 mg upper respiratory tract infection 19.3% (placebo 0%) hyperlipidaemia 11% (placebo 0%) urinary tract infection 9% (placebo 0%) NCT02265705 · Phase 3 4 mg arthralgia 5.2% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT02265705 · Phase 3 4 mg upper respiratory tract infection 9.2% (placebo 0%) hyperlipidaemia 7.5% (placebo 0%) benign prostatic hyperplasia 7.1% (placebo 0%) NCT02265705 · Phase 3 blood creatine phosphokinase increased 6.8% (placebo 0%) upper respiratory tract infection 6.8% (placebo 0%) nasopharyngitis 5.4% (placebo 0%) NCT02265705 · Phase 3 4 mg blood creatine phosphokinase increased 8.3% (placebo 4.1%) liver function test abnormal 8.3% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) NCT01469013 · Phase 2 2 mg hepatic function abnormal 12.5% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) cystitis 4.2% (placebo 4.1%) NCT01469013 · Phase 2 8 mg blood creatine phosphokinase increased 12.5% (placebo 4.1%) hepatic function abnormal 12.5% (placebo 0%) hypercholesterolaemia 12.5% (placebo 0%) NCT01469013 · Phase 2 1 mg nasopharyngitis 8.3% (placebo 12.2%) anaemia 4.2% (placebo 0%) chronic sinusitis 4.2% (placebo 0%) NCT01469013 · Phase 2 4 mg upper respiratory tract infection 10.6% (placebo 0%) nasopharyngitis 7.9% (placebo 0%) blood creatine phosphokinase increased 6.6% (placebo 5.9%) NCT01721057 · Phase 3 4 mg cough 4.5% (placebo 0%) dyspnoea 4.5% (placebo 0%) gastritis 4.5% (placebo 0%) NCT01721057 · Phase 3 2 mg headache 6.6% (placebo 0%) upper respiratory tract infection 6.1% (placebo 0%) urinary tract infection 5.2% (placebo 0%) NCT01721057 · Phase 3 2 mg abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) acne 0% (placebo 0%) NCT01721057 · Phase 3 4 mg cervicitis 5.6% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT01721044 · Phase 3 4 mg headache 6.8% (placebo 0%) bronchitis 5.6% (placebo 0%) nausea 5.6% (placebo 0%) NCT01721044 · Phase 3 2 mg cellulitis 11.1% (placebo 0%) insomnia 11.1% (placebo 0%) lymphopenia 11.1% (placebo 0%) NCT01721044 · Phase 3 2 mg headache 9.8% (placebo 0%) upper respiratory tract infection 8.6% (placebo 0%) nasopharyngitis 6.9% (placebo 5.3%) NCT01721044 · Phase 3 4 mg covid-19 23.3% nasopharyngitis 13.8% urinary tract infection 11.4% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 2 mg covid-19 20.8% nasopharyngitis 11.6% urinary tract infection 11.3% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 4 mg bronchitis 11.3% nasopharyngitis 11.3% upper respiratory tract infection 10.9% NCT01885078 · Phase 3 · registry result, not featured evidence 4 mg bronchitis 10.9% nasopharyngitis 9.8% influenza 9.4% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 19.5% urinary tract infection 17.8% bronchitis 16.2% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.1% upper respiratory tract infection 7.8% bronchitis 7.4% NCT01885078 · Phase 3 · registry result, not featured evidence | g upper respiratory tract infection 19.4% headache 11.1% urinary tract infection 8.3% NCT01262118 · Phase 1 show 70 more results5 mg upper respiratory tract infection 4.1% (placebo 0%) gastroenteritis 2.2% (placebo 0%) nasopharyngitis 1.9% (placebo 0%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 3.5% (placebo 0%) diarrhoea 1.9% (placebo 0%) sinusitis 1.6% (placebo 2.5%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 6% (placebo 0%) nasopharyngitis 5.1% (placebo 0%) diarrhoea 4.4% (placebo 0%) NCT00856544 · Phase 3 10 mg nasopharyngitis 2.8% (placebo 0%) upper respiratory tract infection 2.8% (placebo 0%) oedema peripheral 2.5% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 5.7% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 0%) urinary tract infection 2.2% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 7.2% (placebo 0%) diarrhoea 3.1% (placebo 0%) headache 3.1% (placebo 2.5%) NCT00856544 · Phase 3 5 mg twice daily nasopharyngitis 2.2% (placebo 1.7%) urinary tract infection 2.2% (placebo 0%) fall 1.7% (placebo 3.4%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) nasopharyngitis 3.1% (placebo 1.7%) bronchitis 2.7% (placebo 0%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 4.4% (placebo 0%) headache 3.9% (placebo 0%) nasopharyngitis 3.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily back pain 0.9% (placebo 0%) fall 0.9% (placebo 3.4%) nasopharyngitis 0.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily bronchitis 4% (placebo 0%) abdominal pain upper 2.8% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT00853385 · Phase 3 10 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) headache 3% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00853385 · Phase 3 5 mg upper respiratory tract infection 4.7% (placebo 0%) nasopharyngitis 3.6% (placebo 4.9%) bronchitis 0.8% (placebo 0%) NCT00847613 · Phase 3 5 mg nasopharyngitis 5.5% (placebo 4.9%) upper respiratory tract infection 3.2% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg headache 5.6% (placebo 0%) nasopharyngitis 4.4% (placebo 4.9%) hypertension 3.4% (placebo 0%) NCT00847613 · Phase 3 10 mg bronchitis 2.5% (placebo 0%) nasopharyngitis 2.5% (placebo 4.9%) upper respiratory tract infection 2.5% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 5.6% (placebo 4.9%) urinary tract infection 4.3% (placebo 0%) upper respiratory tract infection 3.8% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 4.1% (placebo 4.9%) cough 2.8% (placebo 0%) diarrhoea 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg rheumatoid arthritis 3.5% (placebo 3%) bronchitis 3% (placebo 0%) nasopharyngitis 3% (placebo 3%) NCT00960440 · Phase 3 5 mg diarrhoea 6% (placebo 3.8%) nasopharyngitis 3.8% (placebo 3%) upper respiratory tract infection 3.8% (placebo 3%) NCT00960440 · Phase 3 10 mg upper respiratory tract infection 4% (placebo 3%) nasopharyngitis 2.5% (placebo 3%) back pain 2% (placebo 1.5%) NCT00960440 · Phase 3 10 mg headache 6% (placebo 0.8%) nasopharyngitis 4.5% (placebo 3%) diarrhoea 3.7% (placebo 3.8%) NCT00960440 · Phase 3 10 mg BID nasopharyngitis 9.8% blood creatine phosphokinase increased 9.1% upper respiratory tract infection 9.1% NCT01039688 · Phase 3 5 mg BID upper respiratory tract infection 21.9% bronchitis 15.2% urinary tract infection 13.1% NCT02092467 · Phase 4 10 mg BID upper respiratory tract infection 21.8% bronchitis 16.7% urinary tract infection 15.1% NCT02092467 · Phase 4 11 mg arthralgia 2.7% alanine aminotransferase increased 1.9% aspartate aminotransferase increased 1.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg alanine aminotransferase increased 3.8% bronchitis 2.6% nasopharyngitis 2.6% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg nasopharyngitis 5% upper respiratory tract infection 4.8% nausea 2.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5 mg bronchitis 1 6.3% alanine aminotransferase increased 0% anemia 0% NCT00413699 · Phase 3 · registry result, not featured evidence 5 mg BID upper respiratory tract infection 20.3% urinary tract infection 14.3% bronchitis 12.6% NCT00413699 · Phase 3 · registry result, not featured evidence 10 mg BID upper respiratory tract infection 18.3% nasopharyngitis 15.4% urinary tract infection 13.3% NCT00413699 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.6% NCT02281552 · Phase 3 · registry result, not featured evidence 5 mg BID nasopharyngitis 58% herpes zoster 15.5% fall 13.4% NCT00661661 · Phase 3 · registry result, not featured evidence 10 mg BID nasopharyngitis 68.6% herpes zoster 21% fall 19% NCT00661661 · Phase 3 · registry result, not featured evidence 11mg MR sars-cov-2 test positive 6.9% urinary tract infection 4.9% headache 3.9% NCT04413617 · Phase 2 · registry result, not featured evidence 400mg MR + 11mg MR urinary tract infection 6.8% sars-cov-2 test positive 3.9% headache 2.9% NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5 mg Twice a Day arthralgia 5.5% (placebo 0%) rheumatoid arthritis 5.5% (placebo 15.8%) NCT02147587 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 5.4% (placebo 7.2%) headache 4.5% (placebo 0.9%) dizziness 2.7% (placebo 0%) NCT01359150 · Phase 2 · registry result, not featured evidence · combination fatigue 13.3% (placebo 0%) hypoaesthesia 13.3% (placebo 0%) nausea 13.3% (placebo 7.1%) NCT00976599 · Phase 2 · registry result, not featured evidence dyspepsia 4% (placebo 2.1%) oedema peripheral 4% (placebo 4.3%) oropharyngeal pain 4% (placebo 0%) NCT01059864 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 11.5% (placebo 11.5%) hypertension 5.8% (placebo 0%) dental caries 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 10 mg hyperlipidaemia 11.3% (placebo 0%) hypercholesterolaemia 5.7% (placebo 0%) nasopharyngitis 5.7% (placebo 11.5%) NCT00687193 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 14.8% (placebo 11.5%) low density lipoprotein increased 11.1% (placebo 0%) constipation 5.6% (placebo 3.8%) NCT00687193 · Phase 2 · registry result, not featured evidence 3 mg nasopharyngitis 7.5% (placebo 11.5%) headache 5.7% (placebo 1.9%) hypercholesterolaemia 3.8% (placebo 0%) NCT00687193 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 11.3% (placebo 11.5%) fall 5.7% (placebo 0%) abdominal discomfort 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 5 mg urinary tract infection 10.2% (placebo 5.9%) diarrhoea 6.1% (placebo 0%) bronchitis 4.1% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 10 mg headache 9.8% (placebo 2.9%) diarrhoea 6.6% (placebo 0%) hypertension 4.9% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 15 mg urinary tract infection 10.5% (placebo 5.9%) bronchitis 7% (placebo 0%) back pain 5.3% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 3 mg diarrhoea 8.8% (placebo 0%) back pain 5.9% (placebo 0%) bronchitis 5.9% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 1 mg urinary tract infection 8.1% (placebo 5.9%) diarrhoea 5.4% (placebo 0%) dizziness 5.4% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 5 mg alanine aminotransferase increased 22.2% (placebo 3.6%) aspartate aminotransferase increased 14.8% (placebo 3.6%) stomach discomfort 11.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 15.4% (placebo 14.3%) alanine aminotransferase increased 7.7% (placebo 3.6%) blood triglycerides increased 7.7% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 3 mg blood cholesterol increased 11.1% (placebo 0%) alanine aminotransferase increased 7.4% (placebo 3.6%) aspartate aminotransferase increased 7.4% (placebo 3.6%) NCT00603512 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 10.7% (placebo 14.3%) headache 7.1% (placebo 3.6%) stomatitis 7.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 5 mg diarrhoea 12.7% (placebo 3.9%) nasopharyngitis 7% (placebo 5.9%) upper respiratory tract infection 7% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 10 mg cough 8.1% (placebo 0%) influenza 6.8% (placebo 2%) nausea 6.8% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg headache 13.4% (placebo 2%) urinary tract infection 9% (placebo 0%) nasopharyngitis 6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg to 5 mg (R) headache 23.1% (placebo 2%) upper respiratory tract infection 15.4% (placebo 2%) abdominal pain upper 7.7% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 8% (placebo 5.9%) alanine aminotransferase increased 6.7% (placebo 2%) aspartate aminotransferase increased 6.7% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg nausea 5.5% (placebo 2%) pharyngitis 5.5% (placebo 3.9%) abdominal pain upper 3.6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg to 5 mg (R) upper respiratory tract infection 23.1% (placebo 2%) arthralgia 15.4% (placebo 0%) headache 15.4% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg diarrhoea 14.3% (placebo 3.9%) abdominal pain upper 4.1% (placebo 5.9%) headache 4.1% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg to 5 mg (R) gastritis 9.5% (placebo 0%) nasopharyngitis 9.5% (placebo 5.9%) oral herpes 9.5% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 5 mg BID headache 16.4% (placebo 9.2%) abdominal pain upper 6.6% (placebo 0%) nausea 6.6% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 30 mg BID headache 24.6% (placebo 9.2%) leukopenia 10.1% (placebo 1.5%) nausea 8.7% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 15 mg BID headache 11.6% (placebo 9.2%) dizziness 5.8% (placebo 1.5%) hypercholesterolaemia 5.8% (placebo 0%) NCT00147498 · Phase 2 · registry result, not featured evidence nasopharyngitis 8.2% (placebo 5.9%) headache 6.2% (placebo 2%) nausea 5.2% (placebo 3.9%) NCT01484561 · Phase 1 · registry result, not featured evidence nausea 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence anemia 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 2 versus Phase 3.
- fAssessment timepoints differ: 273 weeks versus 24 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
+ 73 further endpoints in the CSV export.
tofacitinib
show 35 more results
show 76 more results
show 72 more results
show 76 more results
show 113 more results
show 9 more results
show 203 more results
show 17 more results
show 216 more results
show 96 more results
show 210 more results
show 13 more results
+ 671 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · tofacitinib's landscape